MEDIA

GBC (4117) announced on the 2nd that it has signed a three-year exclusive distribution agreement with a Brazilian distributor to expand into South America. The main products to be sold include ELISA serum antibody assays, hepatitis A/B/C/D testing assays, as well as CLIA chemiluminescence immunoassay and PCR equipment and related reagents. The Brazilian distributor has already partnered with over 40% of local blood centers, accumulating sales channels with more than 200 laboratories and hospitals. Deliveries are expected to gradually commence from April, boosting GBC’s new growth momentum.

GBC indicated that its revenue distribution for the first two months of this year was 42% in Taiwan, 13% in the Middle East, and 2% in Southeast Asia. Additionally, besides existing sales in Mexico, this collaboration with the Brazilian distributor is expected to generate sales momentum for GBC’s precise testing equipment and reagents, further expanding the company’s sales footprint in South America and enhancing its overall international sales strategy.

Leveraging the group’s integrated operations encompassing research and development, manufacturing, clinical trials, and global distribution, GBC aims to complete and launch its AI park facility in Zhubei in the second half of 2024. Continual negotiations with international distributors will also contribute to expanding the operational scale of precise testing and liquid biopsy services, complementing resources with its existing Zhubei factory in the Hsinchu Science Park and bolstering opportunities for international business development.

Looking ahead, GBC is optimistic about the increasing market demand in precision medical testing and liquid biopsy fields, actively enhancing its core business areas including precise testing, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), testing services, and P113 antimicrobial peptide drugs. Participation in key international biotechnology and medical exhibitions will further raise the visibility of the GBC brand and promote order intake for precise testing and liquid biopsy services, thereby creating favorable growth prospects for GBC’s future operations.